Daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) vs daratumumab, carfilzomib, lenalidomide and dexamethasone (DKRd) as induction therapy in newly diagnosed multiple myeloma

被引：0

作者：

Tan, Carlyn Rose ^{[1
]}

Maclachlan, Kylee ^{[2
]}

Nemirovsky, David ^{[3
]}

Derkach, Andriy ^{[1
]}

Hultcrantz, Malin ^{[2
]}

Hassoun, Hani ^{[2
]}

Mailankody, Sham ^{[2
]}

Shah, Urvi ^{[2
]}

Patel, Dhwani ^{[1
]}

Shekarkhand, Tala ^{[1
]}

Rueda, Colin ^{[1
]}

Lahoud, Oscar ^{[1
]}

Shah, Gunjan ^{[1
]}

Scordo, Michael ^{[1
]}

Chung, David ^{[4
]}

Landau, Heather ^{[4
]}

Giralt, Sergio ^{[1
]}

Usmani, Saad ^{[1
]}

Lesokhin, Alexander ^{[1
]}

Korde, Neha ^{[2
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, New York, NY USA

[2] Mem Sloan Kettering Canc Ctr, Dept Med, Myeloma Serv, New York, NY USA

[3] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY USA

[4] Mem Sloan Kettering Canc Ctr, Bone Marrow Transplant & Cellular Therapy, New York, NY USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P166

引用

页码：S127 / S127

页数：1